Stevan N. Djakovic, PhD

Affiliations:

2017-

Clinical Science

Genentech, Inc., San Francisco, CA, United States

Area:

Autophagy, Ubiquitin Proteasome System, Neurodegenerative Disease, oncology

Google:

"Stevan Djakovic"

Bio:

Stevan Djakovic works as a clinical scientist supporting the development of venetoclax for treatment of CLL, at Roche/Genentech.
(Show more)

Mean distance: 16.1 (cluster 11)

Tree Publications Grants Similar researchers PubMed Report error

Parents

Laurie G. Smith	research assistant	2001-2004	UCSD (Plant Biology Tree)
Gentry N. Patrick	grad student	2004-2010	UCSD
(Dynamic regulation of proteasome function by neuronal activity.)
Al La Spada	post-doc	2010-2011	UCSD
Avi Ashkenazi	research scientist	2012-2013	Genentech, Inc.

Children

Collaborators

Sonya K. Jakawich	collaborator		University of Michigan
Michael Sutton	collaborator		UCSD

BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
Le Moigne R, Aftab BT, Djakovic S, et al. (2017) The p97 inhibitor CB-5083 is a unique disrupter of protein homeostasis in models of Multiple Myeloma. Molecular Cancer Therapeutics
Menon M, Soriano F, Wong S, et al. (2016) Abstract 4541: Utilization of K48 poly-ubiquitin modulation as a biomarker of target engagement for a protein homeostasis inhibitor in the clinic: Preclinical validation with CB-5083, a first-in-class inhibitor of the AAA ATPase p97 Cancer Research. 76: 4541-4541
Zhou HJ, Wang J, Yao B, et al. (2015) Discovery of a First-in-Class, Potent, Selective and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083). Journal of Medicinal Chemistry
Anderson DJ, Le Moigne R, Djakovic S, et al. (2015) Targeting the AAA ATPase p97 as an Approach to Treat Cancer through Disruption of Protein Homeostasis. Cancer Cell. 28: 653-65
Yin Y, Djakovic S, Marsters S, et al. (2015) Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Anti-tumor Activity. Molecular Cancer Therapeutics
Nawrocki ST, Han Y, Moigne RL, et al. (2015) Activation of the Unfolded Protein Response with the First-in-Class P97 Inhibitor CB-5083 Induces Stable Disease Regression and Overcomes Ara-C Resistance in AML Blood. 126: 1350-1350
Anderson DJ, Moigne RL, Djakovic S, et al. (2015) Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer Cancer Research. 75
Dubinsky AN, Dastidar SG, Hsu CL, et al. (2014) Let-7 coordinately suppresses components of the amino acid sensing pathway to repress mTORC1 and induce autophagy. Cell Metabolism. 20: 626-38
Aftab BT, Anderson DJ, Le Moigne R, et al. (2014) Pre-Clinical Activity of the Novel, First-in-Class p97 Inhibitor, CB-5083, in Multiple Myeloma Blood. 124: 4701-4701
Tohme R, Moigne RL, Przychodzen BP, et al. (2014) Inhibition of p97 with the First-in-Class Small Molecule CB-5083: A Novel Strategy for Acute Myeloid Leukemia Therapy Blood. 124: 3766-3766